ArticleTranslational oncology2026
Immunohistochemical analysis and scRNA-Seq identifies vascular endothelial CXCR4 expression as a predictor of poor prognosis in pancreatic ductal adenocarcinoma.
Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe clinical significance of C-X-C chemokine receptor 4 (CXCR4) expression at the invasive front of pancreatic ductal adenocarcinoma (PDAC) remains unclear. This study investigated CXCR4 expression in the vascular endothelium at sites of cancer tissue infiltration into the pancreatic surrounding fatty tissue in resected PDAC specimens.
methodsWe prepared tissue microarrays from 80 cases of PDAC resected between 2011 and 2023 and retrospectively analyzed the samples by immunohistochemistry. CXCR4 expression in blood vessels was semi-quantitatively scored (0 to 3+) and categorized as high (2-3+) or low (0-1+). We also analyzed the clinicopathological features associated with CXCR4 expression. Finally, leveraging public databases for single-cell RNA sequencing was used to confirm the localization of CXCR4 expression.
resultsOf the 80 cases, 33 exhibited high CXCR4 expression and 47 showed low expression. The high expression group had a significantly shorter median overall survival (469 versus 1176 days, P = 0.0361). In the multivariate analysis, high CXCR4 expression (hazard ratio 1.8180, 95% confidence interval, 1.0350-3.193, P = 0.0342) was an independent prognostic factor. single-cell RNA sequencing revealed sparse CXCR4 expression in arteries, veins, capillaries, and tip-like endothelial cells.
conclusionVascular endothelial CXCR4 expression at the invasive front of PDAC is associated with poor prognosis and may be associated with tumor progression in correlation with angiogenic mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.